Cadrenal Therapeutics (CVKD) Stock Overview
Operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CVKD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cadrenal Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.96 |
| 52 Week High | US$15.99 |
| 52 Week Low | US$4.21 |
| Beta | 1.83 |
| 1 Month Change | -25.64% |
| 3 Month Change | -41.58% |
| 1 Year Change | -62.79% |
| 3 Year Change | -75.86% |
| 5 Year Change | n/a |
| Change since IPO | -91.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| CVKD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.4% | 0.1% | 1.5% |
| 1Y | -62.8% | 41.1% | 28.6% |
Return vs Industry: CVKD underperformed the US Pharmaceuticals industry which returned 44.6% over the past year.
Return vs Market: CVKD underperformed the US Market which returned 28.4% over the past year.
Price Volatility
| CVKD volatility | |
|---|---|
| CVKD Average Weekly Movement | 13.3% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CVKD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CVKD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 5 | Quang Pham | www.cadrenal.com |
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device.
Cadrenal Therapeutics, Inc. Fundamentals Summary
| CVKD fundamental statistics | |
|---|---|
| Market cap | US$15.27m |
| Earnings (TTM) | -US$11.89m |
| Revenue (TTM) | n/a |
Is CVKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVKD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.89m |
| Earnings | -US$11.89m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.86 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CVKD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/30 04:30 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cadrenal Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |
| Robert LeBoyer | NOBLE Capital Markets, Inc. |
| David Bautz | Zacks Small-Cap Research |